Clinical trials: Thoracic Tumor
Non-Small Cell Lung Cancer
A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab
This is a phase 2 multicenter, open label, randomized study of AMG 951 (rhApo2L/TRAIL) in subjects with previously untreated stage IIIb/IV NSCLC treated with chemotherapy with or without bevacizumab.
- Trial name
- NCT00508625
- Testing
- AMG 951 (rhApo2L/TRAIL), Bevacizumab, Carboplatin
- Volunteers
- 213 people
- Sponsor
- Amgen
Thyroid Cancer, Renal Cell Carcinoma
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of nanrilkefusp alfa as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
- Conditions
- Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer
- Trial name
- NCT04234113
- Testing
- Nanrilkefusp alfa, Pembrolizumab
- Where
- 12 sites in United States, Czechia and 2 more
- Volunteers
- 115 people
- Sponsor
- SOTIO Biotech AG
Non-Small Cell Lung Cancer, Multiple Myeloma
Common Safety Follow-up Trial of Tecemotide (L-BLP25)
This is an open-label, common follow-up trial. Subjects who were enrolled in a Merck KGaA, EMD Serono or Merck Serono Japan sponsored trial with tecemotide (L-BLP25) were enrolled in this follow-up trial to continue their…
- Trial name
- NCT01423760
- Testing
- Tecemotide, No intervention
- Where
- Germany
- Volunteers
- 27 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Lung Cancer
A Study to Learn About Dacomitinib in Patients With Non-small Cell Lung Cancer.
The purpose of this study is to learn about dacomitinib for the possible treatment of lung cancer. This study is seeking participants who: have lung cancer that could not be controlled.
- Trial name
- NCT06321510
- Where
- Taiwan
- Volunteers
- 29 people
- Sponsor
- Pfizer
Lung Cancer
Lung EpiCheck Biomarkers Development Study
This study is part of the development of a non-invasive lung cancer screening test which aim to identify early-stage lung cancer in patients at high risk for lung cancer.
- Trial name
- NCT06245876
- Testing
- Blood collection
- Where
- 10 sites in United States, Hungary and 2 more
- Volunteers
- 2,132 people, healthy volunteers welcome
- Sponsor
- Nucleix Ltd.
Non-small Cell Lung Cancer
A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC
This study was a randomized, controlled, open-label, multicenter phase III clinical study to compare the efficacy and safety of SHR-A2009 with platinum-based dual-agent chemotherapy in patients with EGFR-mutated advanced or…
- Trial name
- NCT06671379
- Testing
- SHR-A2009 monotherapy, platinum-based dual-agent chemotherapy
- Where
- China
- Volunteers
- 498 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Metastatic NSCLC
A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to investigate the efficacy, safety, and immunogenicity of GME751 compared with Keytruda® (pembrolizumab) in participants with untreated metastatic non-squamous NSCLC (irrespective of PD-L1 status)…
- Trial name
- NCT06159790
- Testing
- GME751, Keytruda-EU
- Where
- 62 sites in United States, Bosnia and Herzegovina and 14 more
- Volunteers
- 218 people
- Sponsor
- Sandoz
Non-Small Cell Lung Cancer
Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients
This is a Phase 1/2, multi-center, open-label, dose-escalation trial of Ad-MAGEA3 and MG1-MAGEA3 in combination with pembrolizumab in patients with Non-Small Cell Lung Cancer who have completed a first standard therapy with at…
- Trial name
- NCT02879760
- Testing
- Ad-MAGEA3, MG1-MAGEA3, Pembrolizumab
- Where
- 6 sites in Canada
- Volunteers
- 16 people
- Sponsor
- Turnstone Biologics, Corp.
Non Small Cell Lung Cancer, c-MET
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung.
- Trial name
- NCT04928846
- Testing
- Telisotuzumab Vedotin, Docetaxel
- Where
- 317 sites in United States, Argentina and 30 more
- Volunteers
- 768 people
- Sponsor
- AbbVie
PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or…
- Conditions
- PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation
- Trial name
- NCT06922591
- Testing
- TNG462, RMC-9805, RMC-6236
- Where
- 18 sites in United States
- Volunteers
- 183 people
- Sponsor
- Tango Therapeutics, Inc.
Mesothelioma
An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma
This study is a multicentre, open label, non-comparative, two stage phase II trial to assess the activity of ZD1839 (IRESSA) in patients with malignant mesothelioma.
- Trial name
- NCT00787410
- Testing
- ZD1839
- Volunteers
- 23 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer
The primary objective of this trial is to evaluate the efficacy of trastuzumab deruxtecan in HER2-overexpressing and/or HER2-mutated advanced NSCLC participants.
- Trial name
- DESTINY-Lung01 (NCT03505710)
- Testing
- Trastuzumab deruxtecan
- Where
- 21 sites in United States, France and 3 more
- Volunteers
- 181 people
- Sponsor
- Daiichi Sankyo
Carcinoma, Non-Small-Cell Lung
Real World Data on Gi(l)Otrif® Dose Adjustment
This is a non-interventional, multi-country, multi-site study based on existing data from medical records of patients treated with Gi(l)otrif® as part of the routine treatment according to the approved label.
- Trial name
- NCT02751879
- Where
- 29 sites in United States, Austria and 11 more
- Volunteers
- 228 people
- Sponsor
- Boehringer Ingelheim
Solid Tumors, Lymphomas
A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas
TSR-011 is a potent small molecule inhibitor of tyrosine kinases involved in cancer, including: 1. Anaplastic lymphoma kinase (ALK) 2.
- Trial name
- NCT02048488
- Testing
- TSR-011
- Where
- 15 sites in United States, Poland and 3 more
- Volunteers
- 72 people
- Sponsor
- Tesaro, Inc.
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
A Study of Ivonescimab in First-Line ES-SCLC
The goal of this clinical trial is to learn if different combinations of a drug called Ivonescimab, along with chemotherapy and other investigational drugs, are safe and effective for the initial treatment of adults with…
- Trial name
- NCT07245446
- Testing
- Ivonescimab, Cadonilimab, AK117
- Where
- 3 sites in China
- Volunteers
- 180 people
- Sponsor
- Akeso
Carcinoma, Non-Small-Cell Lung
Gemcitabine in Combination With Cisplatin as Neoadjuvant NSCLC Chemotherapy
To evaluate the clinical response rate of neoadjuvant chemotherapy with gemcitabine and cisplatin in patients with operable NSCLC
- Trial name
- NCT00191841
- Testing
- gemcitabine, Cisplatin
- Where
- 4 sites in Russia
- Volunteers
- 50 people
- Sponsor
- Eli Lilly and Company
Non-small Cell Lung Cancer
Study of XL999 in Patients With Non-small Cell Lung Cancer
This clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of XL999 when given weekly to patients with non-small cell lung cancer (NSCLC).
- Trial name
- NCT00277329
- Testing
- XL999
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Symphony Evolution, Inc.
Non-Small Cell Lung Cancer
A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g)
This is a randomized, double-blind, Phase II, placebo-controlled trial adding on to a background of effective treatment designed to evaluate the efficacy, safety, and pharmacokinetics of PRO95780 combined with paclitaxel +…
- Trial name
- NCT00480831
- Testing
- bevacizumab, carboplatin, paclitaxel
- Volunteers
- 128 people
- Sponsor
- Genentech, Inc.
Lung Cancer
Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC
This is an open-label, interventional, multiple-center, exploratory Phase II study sponsored by AstraZeneca Investment(China)Co., LTD.
- Trial name
- SOUND (NCT05374603)
- Testing
- Savolitinib, Durvalumab
- Where
- 16 sites in China
- Volunteers
- 47 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings
This non-interventional study will include a representative sample of patients with locally advanced or metastatic NSCLC harboring Epidermal Growth Factor Receptor (EGFR)-mutations in Greece.
- Trial name
- NCT02440854
- Testing
- afatinib
- Where
- 7 sites in Greece
- Volunteers
- 80 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.